Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTC-DOX vs IV Doxorubicin in Unresectable Hepatocellular Carcinoma
NCT00034333Phase 3Terminated
- Sponsor
- FeRx
- Start
- Mar 2002
- Modality
- Nanoparticles, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of MTC-doxorubicin in hepatocellular carcinoma (HCC), sponsored by FeRx. Started Mar 2002; status: terminated.
02
Drugs
MTC-doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00034333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034333.